A Somatic BRCA2-Mutated Pancreatic Adenocarcinoma With Sustained Exceptional Response to Modified FOLFIRINOX

Jamison, J. K., May, M. S., Raufi, A. G., Luk, L., Wong, W., Mundi, P. S., & Manji, G. A. (2024). A Somatic BRCA2-Mutated Pancreatic Adenocarcinoma With Sustained Exceptional Response to Modified FOLFIRINOX. The Oncologist, 29(4), 350–355. https://doi.org/10.1093/oncolo/oyad315
Authors:
Jacob K Jamison
Michael S May
Alexander G Raufi
Lyndon Luk
Winston Wong
Prabhjot S Mundi
Gulam A Manji
Affiliated Authors:
Michael S May
Lyndon Luk
Prabhjot S Mundi
Gulam A Manji
Columbia Affiliation:
Subjects:
Adenocarcinoma (MeSH)
Pancreatic Neoplasms (MeSH)
Cancer Survivors (MeSH)
Author Keywords:
pancreatic cancer
precision medicine
homologous recombination deficiency
elink
Publication Type:
Article
Unique ID:
10.1093/oncolo/oyad315
PMID:
38394390
DOI:
10.1093/oncolo/oyad315
Journal:
Oncologist
Publication Date:
Data Source:
PubMed
Source Link:
View PubMed Record
View Scopus Record
View Web of Science Record

Record Created: